By UTCardiothoracicSurgery.com Editorial Team
Title: Cloud9 Review 2026: Supplement Cardiovascular Safety Evaluation
Categories: [22, 30]
FTC Affiliate Disclosure: UTCTS Health Review Editorial Team may earn affiliate commissions from purchases made through recommended product links. All opinions are independent and based on research.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before use, especially if you have cardiovascular disease, take medications, or have any medical conditions.
UTCTS Health Review Editorial Team | July 2026
In This Article
Cloud9 Review 2026: Supplement Cardiovascular Safety Evaluation
Cloud9 Daily Restore is marketed as an alcohol recovery supplement designed to mitigate the effects of drinking on liver health, brain function, and overall wellness. The formula combines liver-supportive ingredients (Milk Thistle, N-acetylcysteine), neurological support compounds (L-Tyrosine, 5-HTP), and adaptogenic herbs (Ashwagandha) alongside vitamins and minerals. For cardiac patients—especially those managing their condition with strict medication protocols—several of Cloud9's ingredients warrant cardiovascular safety scrutiny. The UTCTS Health Review Editorial Team evaluated this product through a cardiac lens and identified potential interaction risks that cardiac patients should understand before use.
Ingredient Profile and Cardiovascular Relevance
Cloud9 contains multiple active ingredients with potential cardiovascular effects:
Milk Thistle (silymarin): Traditionally used for liver support, Milk Thistle is generally considered safe but may have mild vasodilatory properties. In cardiac patients, any vasodilatory effect could interact with blood pressure medications, potentially causing excessive blood pressure reduction.
N-acetylcysteine (NAC): NAC is a precursor to glutathione, a major antioxidant. While typically safe, NAC can increase nitric oxide production, which like other vasodilatory mechanisms, could affect blood pressure regulation in cardiac patients on multiple medications. Some research suggests NAC may increase homocysteine in certain populations, and elevated homocysteine is an independent cardiovascular risk factor.
Ashwagandha (Withania somnifera): This adaptogenic herb is promoted for stress reduction and emotional balance. While generally well-tolerated, Ashwagandha has been associated with mild hypotensive effects. For cardiac patients on blood pressure medication, additive effects could occur.
L-Tyrosine: An amino acid precursor to dopamine, norepinephrine, and epinephrine, L-Tyrosine theoretically could increase sympathetic nervous system activity. In cardiac patients with arrhythmias or those sensitive to sympathomimetic effects, this warrants caution. We also cover this in NeuroMind Pro Review 2026: Nootropic and Cardiac Medication Interactions.
5-HTP: A serotonin precursor used for mood support, 5-HTP can potentially interact with serotonergic medications and may have effects on platelet aggregation and blood clotting—critical considerations in cardiac patients on anticoagulants or antiplatelet agents.
Potassium: Cloud9 includes potassium for electrolyte support. Cardiac patients, particularly those on ACE inhibitors, ARBs, or potassium-sparing diuretics, already run risk of hyperkalemia. Additional potassium supplementation could push serum potassium into dangerous territory.
Drug Interaction Risks for Cardiac Patients
Interactions with Blood Pressure Medications: The combination of Milk Thistle, NAC, and Ashwagandha creates a cumulative hypotensive effect. Patients on beta-blockers, ACE inhibitors, ARBs, or calcium channel blockers could experience unexpected blood pressure drops, dizziness, or reduced cardiac perfusion.
Interactions with Anticoagulants/Antiplatelet Agents: NAC and 5-HTP may interfere with blood clotting mechanisms. Cardiac patients taking warfarin, aspirin, or novel anticoagulants (dabigatran, apixaban) should avoid Cloud9 without physician approval. The risk of bleeding complications is real.
Potassium Overload Risk: For cardiac patients on potassium-sparing medications (spironolactone, eplerenone, ACE inhibitors, ARBs), the added potassium in Cloud9 creates hyperkalemia risk. Elevated serum potassium can trigger fatal arrhythmias in cardiac patients.
SSRIs and Serotonin Syndrome: The 5-HTP component combined with selective serotonin reuptake inhibitors (SSRIs, commonly used in cardiac patients for depression or anxiety) increases serotonin syndrome risk—characterized by agitation, elevated heart rate, fever, and muscle rigidity. This is a potentially serious interaction.
Alcohol Recovery Context and Cardiac Risk
Cloud9 is specifically designed for individuals who drink alcohol. It is important to note that alcohol itself is cardiotoxic in excess. Chronic heavy drinking causes cardiomyopathy, arrhythmias, and hypertension. Cardiac patients with alcohol use disorder require comprehensive medical management, not supplementation alone. Furthermore, individuals recovering from acute alcohol intoxication experience dehydration, electrolyte depletion, and sympathetic nervous system hyperactivity. Adding L-Tyrosine (which increases catecholamines) could theoretically worsen sympathetic overdrive in the immediate post-drinking period.
Who This Is NOT For
Cardiac patients should NOT use Cloud9 if they:
- Take blood pressure medications (beta-blockers, ACE inhibitors, ARBs, calcium channel blockers)
- Are on anticoagulant or antiplatelet therapy (warfarin, aspirin, novel anticoagulants)
- Take SSRIs or other serotonergic medications
- Are on potassium-sparing diuretics or ACE inhibitors/ARBs (hyperkalemia risk)
- Have arrhythmias or are arrhythmia-prone
- Have reduced ejection fraction or heart failure
- Are in the acute recovery phase from myocardial infarction
Safe Alcohol Recovery and Cardiac Protection
Cardiac patients with alcohol concerns should work with both a cardiologist and an addiction medicine specialist or psychiatrist. Evidence-based approaches include supervised alcohol cessation, cardiac rehabilitation, electrolyte monitoring and replacement when needed, and management of any resulting hypertension or arrhythmias. Medication-assisted treatment options exist for alcohol use disorder and can be tailored to cardiac safety.
The Bottom Line
Cloud9 Daily Restore combines multiple ingredients with potential cardiovascular effects: vasodilatory compounds (Milk Thistle, NAC, Ashwagandha) that could dangerously lower blood pressure in cardiac patients; serotonergic components (5-HTP) that interact with SSRIs; and potassium supplementation that risks hyperkalemia in patients on common cardiac medications. The cumulative interaction profile makes Cloud9 inadvisable for the majority of cardiac patients. Cardiac patients requiring alcohol recovery support should pursue medically supervised programs with their cardiologist, not supplementation.
Related reading: Omnihear Review 2026: Hearing Supplement Cardiac Safety Evaluation